MX2016013857A - Anticuerpos anti-rnf43 novedosos y metodos de uso. - Google Patents
Anticuerpos anti-rnf43 novedosos y metodos de uso.Info
- Publication number
- MX2016013857A MX2016013857A MX2016013857A MX2016013857A MX2016013857A MX 2016013857 A MX2016013857 A MX 2016013857A MX 2016013857 A MX2016013857 A MX 2016013857A MX 2016013857 A MX2016013857 A MX 2016013857A MX 2016013857 A MX2016013857 A MX 2016013857A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antii
- novel
- rnf43 antibodies
- rnf43
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461982294P | 2014-04-21 | 2014-04-21 | |
PCT/US2015/026904 WO2015164392A2 (en) | 2014-04-21 | 2015-04-21 | Novel antii-rnf43 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016013857A true MX2016013857A (es) | 2017-07-14 |
Family
ID=54333409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013857A MX2016013857A (es) | 2014-04-21 | 2015-04-21 | Anticuerpos anti-rnf43 novedosos y metodos de uso. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20170073430A1 (ru) |
EP (1) | EP3134121A4 (ru) |
JP (1) | JP2017518040A (ru) |
KR (1) | KR20170010764A (ru) |
CN (1) | CN106714831A (ru) |
AU (1) | AU2015249887A1 (ru) |
BR (1) | BR112016024525A2 (ru) |
CA (1) | CA2946308A1 (ru) |
CL (2) | CL2016002667A1 (ru) |
CR (1) | CR20160486A (ru) |
DO (1) | DOP2016000283A (ru) |
EA (1) | EA201692100A8 (ru) |
IL (1) | IL248399A0 (ru) |
MA (1) | MA39896A (ru) |
MX (1) | MX2016013857A (ru) |
PH (1) | PH12016502061A1 (ru) |
SG (1) | SG11201608715WA (ru) |
WO (1) | WO2015164392A2 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6278598B2 (ja) | 2010-11-30 | 2018-02-14 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
TW201800420A (zh) * | 2016-05-20 | 2018-01-01 | 艾伯維史坦森特瑞斯有限責任公司 | 抗ascl1抗體及使用方法 |
EP3568158A4 (en) * | 2017-01-11 | 2020-11-18 | The Board of Trustees of the Leland Stanford Junior University | R-SPONDIN SUBSTITUTION MOLECULES (RSPO) |
AU2018211985A1 (en) | 2017-01-26 | 2019-07-18 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
WO2018203567A1 (en) * | 2017-05-02 | 2018-11-08 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US20200339687A1 (en) * | 2018-01-19 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
JP2021530223A (ja) * | 2018-07-09 | 2021-11-11 | スロゼン, インコーポレイテッド | 組織特異性Wntシグナル増強分子及びその使用 |
EP3877399A4 (en) * | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
WO2020257758A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
US20240002479A1 (en) * | 2020-11-23 | 2024-01-04 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
CN112480250B (zh) * | 2020-12-23 | 2022-03-15 | 上海交通大学 | 一种抗人骨桥蛋白的抗体及其应用 |
JP2024509695A (ja) * | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
CA3211478A1 (en) | 2021-03-16 | 2022-09-22 | Naoya Tsurushita | Bifunctional molecules for treatment of immune disorders |
CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
WO2024025878A2 (en) * | 2022-07-25 | 2024-02-01 | Memorial Sloan-Kettering Cancer Center | Manufacturing processes for adoptive cell therapies |
CN117801108B (zh) * | 2023-12-06 | 2024-06-07 | 无锡傲锐东源生物科技有限公司 | 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101613406A (zh) * | 2002-06-06 | 2009-12-30 | 肿瘤疗法科学股份有限公司 | 与人结肠癌相关的基因和多肽 |
SG10201501103RA (en) * | 2006-05-30 | 2015-04-29 | Genentech Inc | Antibodies And Immunoconjugates And Uses Therefor |
EP3653222A1 (en) * | 2011-10-14 | 2020-05-20 | Novartis AG | Antibodies and methods for wnt pathway-related diseases |
US20150125857A1 (en) * | 2012-02-28 | 2015-05-07 | Novartis Ag | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
-
2015
- 2015-04-21 CA CA2946308A patent/CA2946308A1/en not_active Abandoned
- 2015-04-21 BR BR112016024525A patent/BR112016024525A2/pt not_active IP Right Cessation
- 2015-04-21 AU AU2015249887A patent/AU2015249887A1/en not_active Abandoned
- 2015-04-21 KR KR1020167032459A patent/KR20170010764A/ko unknown
- 2015-04-21 MA MA039896A patent/MA39896A/fr unknown
- 2015-04-21 JP JP2016563850A patent/JP2017518040A/ja active Pending
- 2015-04-21 MX MX2016013857A patent/MX2016013857A/es unknown
- 2015-04-21 CN CN201580033599.1A patent/CN106714831A/zh active Pending
- 2015-04-21 SG SG11201608715WA patent/SG11201608715WA/en unknown
- 2015-04-21 EA EA201692100A patent/EA201692100A8/ru unknown
- 2015-04-21 WO PCT/US2015/026904 patent/WO2015164392A2/en active Application Filing
- 2015-04-21 CR CR20160486A patent/CR20160486A/es unknown
- 2015-04-21 EP EP15783044.9A patent/EP3134121A4/en not_active Withdrawn
- 2015-04-21 US US15/305,861 patent/US20170073430A1/en not_active Abandoned
-
2016
- 2016-10-17 PH PH12016502061A patent/PH12016502061A1/en unknown
- 2016-10-19 IL IL248399A patent/IL248399A0/en unknown
- 2016-10-19 DO DO2016000283A patent/DOP2016000283A/es unknown
- 2016-10-20 CL CL2016002667A patent/CL2016002667A1/es unknown
-
2017
- 2017-12-15 CL CL2017003240A patent/CL2017003240A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12016502061A1 (en) | 2016-12-19 |
CL2016002667A1 (es) | 2017-07-07 |
WO2015164392A8 (en) | 2016-12-29 |
KR20170010764A (ko) | 2017-02-01 |
AU2015249887A1 (en) | 2016-11-03 |
WO2015164392A2 (en) | 2015-10-29 |
EA201692100A8 (ru) | 2018-11-30 |
US20170073430A1 (en) | 2017-03-16 |
EP3134121A2 (en) | 2017-03-01 |
MA39896A (fr) | 2017-03-01 |
EP3134121A4 (en) | 2017-11-08 |
WO2015164392A3 (en) | 2015-12-23 |
JP2017518040A (ja) | 2017-07-06 |
SG11201608715WA (en) | 2016-11-29 |
BR112016024525A2 (pt) | 2017-10-10 |
CR20160486A (es) | 2017-02-20 |
CL2017003240A1 (es) | 2018-06-01 |
CN106714831A (zh) | 2017-05-24 |
DOP2016000283A (es) | 2016-11-30 |
EA201692100A1 (ru) | 2017-02-28 |
CA2946308A1 (en) | 2015-10-29 |
IL248399A0 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
TN2015000396A1 (en) | Antibody drug conjugates | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
MD20170032A2 (ru) | Антитела анти-TIGIT | |
MX2017003022A (es) | Anticuerpos anti-cll-1 e inmunoconjugados. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
MX2019004690A (es) | Constructos de anticuerpos. | |
TN2016000472A1 (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer. | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. |